This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Inogen (INGN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inogen's (INGN) second-quarter results benefit from higher revenues in its international business-to-business sales channel.
Allscripts (MDRX) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Allscripts' (MDRX) robust Q2 results demonstrate strength in both segments.
ZBH vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ZBH vs. LMAT: Which Stock Is the Better Value Option?
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, 2022 View Up
by Zacks Equity Research
The contraction in Zimmer Biomet's (ZBH) gross margin is concerning.
Zimmer Biomet (ZBH) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 11.66% and 3.31%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 37.40% and 3.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: NuVasive (NUVA) Q2 Earnings Expected to Decline
by Zacks Equity Research
NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Zimmer Biomet (ZBH) Q2 Earnings Expected to Decline
by Zacks Equity Research
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet (ZBH) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet's (ZBH) S.E.T. arm is expected to deliver strong results on the back of the company's focus on sports and extremities, especially upper extremities, trauma and CMFT.
Zimmer (ZBH) Down 5.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Retain Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet's (ZBH) better-than-expected revenues and robust performance across several geographies.
Zimmer Biomet's (ZBH) Procedure Volume Grows, Costs Rise
by Zacks Equity Research
Zimmer Biomet's (ZBH) recently completed the spin-off of the non-core dental and spine business is expected to prove strategic.
Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, FY22 View Up
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions recorded year-over-year sales growth at CER.
Zimmer Biomet (ZBH) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 15% and 4.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Zimmer Biomet (ZBH) This Earnings Season?
by Zacks Equity Research
Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect strong performance at Technologies & Equipment business.
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) might have struggled to maintain the recovery trend in the first half of Q1 with severe-than-expected staffing shortages and supply issues leading to procedural deferrals.
PerkinElmer (PKI) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results are likely to reflect strong performance at the Diagnostics segment.
AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
The Zacks Analyst Blog Highlights Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical
by Zacks Equity Research
Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical have been included in this Analyst Blog.
What's in Store for West Pharmaceutical's (WST) Q1 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter results are likely to reflect strength in the Proprietary Products business.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter results are likely to reflect rising global awareness of its real-time CGM.
3 Medical Product Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how ALC, ZBH and CSII are poised ahead of their earnings releases.